<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02251353</url>
  </required_header>
  <id_info>
    <org_study_id>IMET</org_study_id>
    <nct_id>NCT02251353</nct_id>
  </id_info>
  <brief_title>Intervention to Hepatic and Pulmonary Metastasis in Breast Cancer Patients</brief_title>
  <acronym>IMET</acronym>
  <official_title>Intervention to Hepatic and Pulmonary Metastasis in Breast Cancer Patients: Prospective, Observational, Multi-institutional Registration Study - IMET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation of Breast Diseases Societies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation of Breast Diseases Societies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The number of intervention performed for metastatic breast cancer has dramatically increased&#xD;
      over the past 2 decades. Hepatectomy and pulmonary resection for stage IV colorectal cancer&#xD;
      is now considered the standard of care for resectable patients with isolated hepatic and/or&#xD;
      pulmonary disease and acceptable performance status. However, the indications for resection /&#xD;
      intervention of breast cancer origin metastases are not as clearly defined. The aim of this&#xD;
      study to focus on emerging data for the intervention (resection and/or radiofrequency&#xD;
      ablation (RFA), transcatheter arterial chemoembolization (TACE), cyberKnife stereotactic&#xD;
      radiosurgery) of breast cancer metastatic disease to the lung and liver, with a focus on&#xD;
      indications for resection / intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose Despite breast cancer being the most common cancer in women in the developed world,&#xD;
      only a minority of patients (&lt; 10%) has stage IV disease at diagnosis (1). In addition,&#xD;
      20-30% of patients with early breast cancer will experience distant metastatic relapse (2).&#xD;
      Due to advances in available multimodality therapies and a better understanding of tumor&#xD;
      biology, survival of stage IV patients is constantly improving (3-5).&#xD;
&#xD;
      Clinically, oligometastatic breast cancer is characterized by solitary/few detectable&#xD;
      lesions, usually limited to single organs, in which local therapy with curative intent could&#xD;
      impact survival. This population of 'potentially curable' stage IV disease is estimated to be&#xD;
      1-10% of newly diagnosed patients with metastatic breast cancer (5). A multimodal approach is&#xD;
      endorsed for these selected patients (5,6). The identification of patients with truly&#xD;
      oligometastatic disease is challenging. Most published series refer to an era before modern&#xD;
      imaging (i.e. positron emission tomography-computed tomography), and thus many patients were&#xD;
      probably understaged, potentially leading to underestimation of the global effect of an&#xD;
      aggressive local management.&#xD;
&#xD;
      Patients with oligometastatic disease can be divided into 3 cohorts (7,8): 1) patients who&#xD;
      present with oligometastases; 2) patients with residual oligometastases after systemic&#xD;
      therapy; and 3) those with relapsed oligometastases after curative locoregional therapy.&#xD;
      These different groups have possibly distinct prognoses, and may need differential&#xD;
      approaches.&#xD;
&#xD;
      Several series have reported on lung and liver metastases resection in oligometastatic breast&#xD;
      cancer and most data are from small series of patients collected over many years. The largest&#xD;
      dataset comes from the International Registry of Lung Metastases and presents results of lung&#xD;
      metastasectomy in 467 breast cancer patients (9). Complete resection was possible in 84% of&#xD;
      patients and led to a median survival of 37 months (5-year OS = 38%, 10-year OS = 22%).&#xD;
      Identified prognostic factors for lung resection include disease-free interval and number of&#xD;
      metastases (disease-free interval &gt;36 months and solitary metastases being the most&#xD;
      favorable), ER status, size of metastases, completeness of resection, and use of anatomical&#xD;
      resection (as opposite to wedge resection) (9-19). Obviously, the reported data refer to a&#xD;
      subset of patients who were selected for favorable prognostic factors, and any comparison&#xD;
      with surgically untreated patients is threatened by serious biases.&#xD;
&#xD;
      Pulmonary resection in metastatic breast cancer patients, apart from its potential&#xD;
      therapeutic value, is also an important diagnostic tool, especially in patients with a&#xD;
      suspected first recurrence, allowing for differential diagnosis with second primary lung&#xD;
      cancers and benign lesions (19,20). The proportion of lesions proved not to be breast cancer&#xD;
      metastases in various series ranges from 7% to 66% (9,14,18,21). As the morbidity and&#xD;
      mortality of pulmonary resection has decreased substantially over the last decades, this&#xD;
      potentially beneficial procedure can be discussed in a selected group of patients (9,19,21).&#xD;
&#xD;
      Surgery to remove liver metastases is an accepted treatment modality in patients with&#xD;
      colorectal cancer (22). Its role in breast cancer is, however, much less recognized. Liver is&#xD;
      a common metastatic breast cancer site, but only 5% of patients have isolated liver&#xD;
      involvement. In various series of hepatic resection for breast cancer metastases, the&#xD;
      reported median survival ranged from 14.5 to 63 months and the 5-year survival from 14% to&#xD;
      61%, in general, comparing well with nonsurgically treated patients. Most of the reported&#xD;
      series, however, describe extremely selected patients, constituting 1% or less of metastatic&#xD;
      breast cancer patients treated over the respective periods of time (22-26). As an example, in&#xD;
      the one of the important series, all patients were asymptomatic and identified through&#xD;
      intensive surveillance programs (27). Patients with isolated liver metastasis can potentially&#xD;
      be managed with local treatments (surgery, radiofrequency ablation (RFA), transcatheter&#xD;
      arterial chemoembolization (TACE), cyberKnife stereotactic radiosurgery). In contrast to&#xD;
      liver colorectal metastases, local treatment for breast cancer liver metastasis is not&#xD;
      considered a therapeutic option due to common involvement of additional organs; nevertheless,&#xD;
      in some selected patients, local approaches have been associated with long-term survival&#xD;
      (10,29,30).&#xD;
&#xD;
      Because patients who are potentially eligible for this therapeutic strategy represent only&#xD;
      1%-3% of the total metastatic breast cancer population, a large global collaboration is&#xD;
      needed to confirm its impact on long-term survival or cure and to ensure adequate statistical&#xD;
      power and strength of the results. Enrolled patients must have comparable clinical and&#xD;
      biological characteristics, extent of staging, and frequency of monitoring to avoid selection&#xD;
      biases and stage migration, which can substantially affect the outcome.&#xD;
&#xD;
      The number of intervention performed for metastatic breast cancer has dramatically increased&#xD;
      over the past 2 decades. Hepatectomy and pulmonary resection for stage IV colorectal cancer&#xD;
      is now considered the standard of care for resectable patients with isolated hepatic and/or&#xD;
      pulmonary disease and acceptable performance status. However, the indications for resection /&#xD;
      intervention of breast cancer origin metastases are not as clearly defined. The aim of this&#xD;
      study to focus on emerging data for the intervention (resection and/or radiofrequency&#xD;
      ablation (RFA), transcatheter arterial chemoembolization (TACE), cyberKnife stereotactic&#xD;
      radiosurgery) of breast cancer metastatic disease to the lung and liver, with a focus on&#xD;
      indications for resection / intervention.&#xD;
&#xD;
      Patient acquisition and data collection All patient should be female. All following&#xD;
      demographic, clinical and tumour specific data will be collected: patient age, performance&#xD;
      status according to the WHO classification at the time of first presentation to the hospital,&#xD;
      stage, type and receptor status (ER, PR, HER-2) of the primary tumour, tumor load in the lung&#xD;
      and/or liver (uni-or bilateral affection, number of metastases, diameter of the largest&#xD;
      tumour size), chronology of the metastases (metachronous or synchronous), presence of further&#xD;
      metastatic (synchronous metastases) or recurrent (metachronous) extrahepatic tumour growth&#xD;
      and lymph node involvement in the mediastinal region or hepatoduodenal ligament. In addition,&#xD;
      treatment-related and follow-up data will be documented: Intervention method (surgical&#xD;
      resection, cryosurgery, laser-induced thermotherapy, radio-frequency ablation, ethanol&#xD;
      injection, cyber-knife), median follow-up, incidence of tumour recurrence, time to&#xD;
      recurrence, overall survival, and the administration of chemotherapy. Survival will be&#xD;
      calculated from the date of diagnosis of the lung and/or liver metastases.&#xD;
&#xD;
      Definitions Lung and/or liver metastases will be defined as metachronous if the interval&#xD;
      between resection of the primary tumour and first diagnosis of metastases is longer than 3&#xD;
      months. General physical condition of study patients will be measured by the performance&#xD;
      status according to the WHO classification.&#xD;
&#xD;
      Prior and during the treatment, all patients will be undergone evaluation with complete&#xD;
      medical history, physical examination, baseline blood tests, and imaging evaluations&#xD;
      (positron emission tomography (PET-CT) and/or radiography, bone scintigraphy, computed&#xD;
      tomography scan, magnetic resonance imaging, ultrasonography). Effects of the treatment will&#xD;
      be monitoring by imaging analyses at every 3 months for lesions detected at diagnosis of lung&#xD;
      and/or hepatic metastasis or every 6 months without detectable lesions before the treatment.&#xD;
&#xD;
      R0 resection is a complete resection with no microscopic residual tumor, while R1 resection&#xD;
      means a complete resection with no grossly visual tumor as defined by surgeon, but&#xD;
      microscopic cancer may be left behind. R2 resection indicates a partial resection with&#xD;
      grossly visible tumor left behind.&#xD;
&#xD;
      Effects of the treatment were assessed by analyses of maximum response, according to either&#xD;
      the criteria of the World Health Organization (WHO) (30) or the Response Evaluation Criteria&#xD;
      in Solid Tumors (RECIST) version 1.0 (31) since its announcement in 2004. Responses in bone&#xD;
      metastases were evaluated using the methods reported by MD Anderson Cancer Center (32,33),&#xD;
      with CR as clear evidence of complete bone recalcification with attainment of near-normal&#xD;
      bone architecture or normalization of scan, and partial response as radio- logical evidence&#xD;
      of sclerosis in lytic lesions or marked improvement of bone scan. In recent years, MRI was&#xD;
      performed when available, and the imaging information was taken into account in evaluation of&#xD;
      bone metastases. Responses in pleural fluids were determined as: CR for radiological&#xD;
      demonstration of complete disappearance of pleural fluid, and PR for 50% or more decrease.&#xD;
      For study inclusion, pathological diagnosis of the primary lesions had to be obtained,&#xD;
      whereas tissue or cellular pathology of the metastatic lesions was preferred but not&#xD;
      mandatory. In patients who performed surgical resection, a complete histopathological&#xD;
      response will be defined as the absence of vital tumour cells. Detection of tumour necrosis&#xD;
      or scar formation within the tumour tissue will be regarded as a partial pathohistological&#xD;
      response.&#xD;
&#xD;
      Ethics committee approval in Istanbul University Istanbul Medical Faculty can be obtained to&#xD;
      participate for this study.&#xD;
&#xD;
      Statistical analysis The characteristics of the patients with assessable data will be&#xD;
      compared with X2 test or Wilcoxon rank-sum tests. Overall survival (OS) will be defined as&#xD;
      duration from diagnosis of the metastasis to last visit or death. Progression free interval&#xD;
      (PFI) will be defined as duration from diagnosis of the metastasis to the point when disease&#xD;
      progression will be detected. Complete response (CR) will be achieved by a systemic therapy&#xD;
      or no evidence of clinical disease (NED) after a local therapy considered relapse-free, and&#xD;
      the duration between induction of relapse free status and the point of relapse detection will&#xD;
      be defined as the relapse free interval (RFI); survival time after induction of relapse-free&#xD;
      status without relapse will be defined as relapse free survival (RFS). Unrelated death other&#xD;
      than from breast cancer will be considered as censored in evaluation of PFI and RFI. Survival&#xD;
      curves will be calculated according to the Kaplan-Meier method. The log-rank test will be&#xD;
      used to evaluate differences in survival between groups with intervention and&#xD;
      no-intervention. A multivariate analysis will be performed by Cox regression and the&#xD;
      following variables will be included: age, DFI, performance status (PS), liver metastasis,&#xD;
      pulmonary metastasis, presence of other metastasis, hormone receptor status, HER2 status,&#xD;
      Ki-67 status, intrinsic subtype, administration of local therapy, and chemotherapy regimens.&#xD;
      Statistical significance will be defined as a p value &lt;0.05. All p values will be calculated&#xD;
      for two-sided analyses. For observed survival, all deaths will be considered as events&#xD;
      including patients who died from secondary causes without recurrence. Statistical analyses&#xD;
      will be performed using SPSS 22.0 (SPSS, Chicago, IL) software.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>Time interval between diagnosis and death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Time interval between diagnosis and first date of progression of disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity due to treatment modality</measure>
    <time_frame>6 months</time_frame>
    <description>Morbidity due to treatment modality</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Metastasis</condition>
  <arm_group>
    <arm_group_label>lung and/or hepatic metastasis</arm_group_label>
    <description>intervention to metastasis (resection and/or radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE), cyberKnife stereotactic radio surgery) vs no intervention (only systemic treatment)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intervention</intervention_name>
    <description>hepatic and/or pulmonary resection, radiofrequency ablation (RFA), transcatheter arterial chemoembolization, CyberKnife stereotactic radiosurgery</description>
    <arm_group_label>lung and/or hepatic metastasis</arm_group_label>
    <other_name>Surgery, Chemotherapy,stereotactic radiosurgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>systemic treatment</intervention_name>
    <description>Systemic therapy</description>
    <arm_group_label>lung and/or hepatic metastasis</arm_group_label>
    <other_name>no intervention</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Breast cancer patients: 1) who present primary tumor with lung and/or hepatic metastases;&#xD;
        2) those with residual lung and/or hepatic metastases after systemic therapy; and 3) those&#xD;
        with relapsed lung and/or hepatic metastases after curative locoregional therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Metastatic breast cancer (lung and/or hepatic metastasis) 18 years and older Antineoplastic&#xD;
        treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        No lung and/or hepatic metastasis Below 18 years No antineoplastic treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lutfi Dogan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ankara Oncology Research and Training Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beyza Ozcinar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hasan Karanlik, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Istanbul University Institute of Oncology Capa Istanbul</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Atilla Soran</last_name>
    <role>Study Director</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Serdar Ozbas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ankara Guven Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lutfi Dogan, MD</last_name>
    <phone>+905057134549</phone>
    <email>lutfidogan1@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beyza Ozcinar, MD</last_name>
    <email>drbeyza@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istanbul University Istanbul Medical Faculty</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vahit Ozmen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Neslihan Cabioglu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 25, 2014</study_first_submitted>
  <study_first_submitted_qc>September 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2014</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federation of Breast Diseases Societies</investigator_affiliation>
    <investigator_full_name>Hasan KaranlÄ±k</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>breast cancer, intervention to metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

